The Clinical Management of Patients with Recurrent Prostate Cancer: Integrative Review
Published: 2023-12-12
Page: 879-889
Issue: 2023 - Volume 6 [Issue 4]
Bolzan V. *
Programa de Pós-Graduação em Tecnologias Radiológicas, Campus Florianópolis, Instituto Federal de Santa Catarina –IFSC, Av. Mauro Ramos, 950 - Centro, Florianópolis - SC, 88020-300, Brazil and Serviço de Medicina Nuclear - Bionuclear (R. Prof. Herminio Jacques, 166 - Centro, Florianópolis - SC, 88015-180), Brazil.
Claus V. T.
Programa de Pós-Graduação em Tecnologias Radiológicas, Campus Florianópolis, Instituto Federal de Santa Catarina –IFSC, Av. Mauro Ramos, 950 - Centro, Florianópolis - SC, 88020-300, Brazil and Serviço de Radioterapia do Hospital Universitário de Santa Maria - HUSM (AV. Roraima, 1000 - Camobi, Santa Maria- RS, 97105 – 900), Brazil.
Baumhardt T.
Serviço de Radioterapia do Hospital Universitário de Santa Maria - HUSM (AV. Roraima, 1000 - Camobi, Santa Maria- RS, 97105 – 900), Brazil.
Schmeling F. T.
Programa de Pós-Graduação em Tecnologias Radiológicas, Campus Florianópolis, Instituto Federal de Santa Catarina –IFSC, Av. Mauro Ramos, 950 - Centro, Florianópolis - SC, 88020-300, Brazil and Liga Catarinense de Combate ao Câncer (Largo São Sebastião 72, Florianópolis - SC, 88015-530), Brazil.
Silva C.
Serviço de Medicina Nuclear do Hospital Universitário de Santa Maria - HUSM (AV. Roraima, 1000 - Camobi, Santa Maria - RS, 97105 – 900), Brazil.
Amaral I.
Curso de Física Médica, Universidade Franciscana - UFN, (R. dos Andradas, 1614 - Centro, Santa Maria - RS, 97010-030), Brazil.
Fetzer J.
Curso de Física Médica, Universidade Franciscana - UFN, (R. dos Andradas, 1614 - Centro, Santa Maria - RS, 97010-030), Brazil.
*Author to whom correspondence should be addressed.
Abstract
SAMPLE ABSTRACT: The 68Ga-PSMA PET/CT precision increase in the Biochemical Recurrence (BR) cell detection brings new challenges in the patients clinical management, specially on RT. Although the RT treatment is a well established practice in 70% of the Prostate Cancer (PCa) patients, 30% to 40% of them show BR after the local Radiotherapy (RT). However, therapeutic innovations, modern imaging techniques and molecular characteristics advances are raising the survival time of recurrent PCa patients. Using target molecules and radiotracers combinations, it was possible to get promising results with radiopharmaceutical therapy directed to PMSA.
Aims: This study aims to analyze the new challenges in the clinical management of patients with recurrent PCa through the advent of 68Ga-PSMA PET/CT imaging.
Study Design: The bibliographic research of the published articles was realized on the electronic databases: PubMed. The article inclusion criteria, previously defined to the review were: articles in portuguese, spanish or english, between 2016 and 2023, with the abstract and full works online. Articles that were not related were excluded.
Place and Duration of Study: between 2016 and 2023.
Methodology: The method used was an integrative literature review, through the search for publications in journals indexed in the PubMed databases. 44 articles were identified, from which 30 were removed: 22 being diagnostic studies and 9 being equipment quality control studies. 14 works were selected for the final sample of the study. All of them using 68Ga-PSMA PET/CT in the patient clinical management submitted to RT and 8 identified using other means.
Results: According to the European Association of Urology, BCR is the second of ten controversial areas in the management of patients with advanced PCa. Currently, the binding of the Gallium-68 radiotracer to the prostate-specific membrane antigen (PSMA) for Positron Emission Tomography (PET/CT 68Ga-PSMA) imaging in patients may allow for a more rational selection of subsequent ideal therapy, although PSMA is not overexpressed in all PCa cases. The use of 68Ga-PSMA PET/CT and RT has shown promise in several studies for recurrent PCa. It is indeed emerging to increase sensitivity and change the treatment landscape. This is an active area of research that has a significant impact on the clinical management of patients, spanning from conventional techniques to advanced Stereotactic Body Radiotherapy (SBRT).
Conclusion: The presented data on this study collaborate with the 68Ga-PSMA PET/CT on the recurrent PCa patients, specially on the selection on to the target molecular therapy. It has become an active investigation, presenting new challenges on the conventional and Hypofractionated (HF) RT on SBRT techniques to the PCa treatment. As research and technology continue to advance, the use of PSMA and other specific markers for diagnosis and treatment is likely to become more refined and widespread. The use of 177Lu-PSMA suggests that molecular targeted therapy is a promising area of development, potentially offering more effective and less invasive treatments for prostate cancer.
Keywords: Stereotactic body radiotherapy, prostate neoplasms, PET-CT, PSA
How to Cite
Downloads
References
Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Hermann K. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). European journal of nuclear medicine and molecular imaging. 2023;50(9):2830–2845. Available:https://doi.org/10.1007/s00259-023-06255-8
Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Omlin A. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European urology. 2020;77(4): 508–547. Available:https://doi.org/10.1016/j.eururo.2020.01.012
Bouchelouche K, Turkbey B, Choyke PL. PSMA PET and radionuclide therapy in prostate cancer. In Seminars in nuclear medicine. 2016;46(6):522-535.WB Saunders.
Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Haberkorn U. Diagnostic performance of 68 Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. European journal of nuclear medicine and molecular imaging. 2017;44:1258-1268.
Slaoui A, Desmet A, Regragui S, Mesfioui A, Ameur A, Peltier A. Pelvic salvage (SBRT) radiotherapy based on 68Ga-PSMA PET/CT: About a case. Urology case reports. 2019;23:95–96. Available:https://doi.org/10.1016/j.eucr.2019.01.014
Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Kumar AR, Thang, SP, Eu P, Scalzo M, Murphy D, Williams S, Hicks RJ, Hofman MS. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2019;60(4):517–523 Available:https://doi.org/10.2967/jnumed.118.219352
da Costa Santos CM, de Mattos Pimenta CA, Nobre MR. The PICO strategy for the research question construction and evidence search. Revista latino-americana de enfermagem. 2007; 15(3):508–511. Available:https://doi.org/10.1590/s0104-11692007000300023
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. International journal of surgery. 2021;88:105906.
Mendes, Karina Dal Sasso; Silveira, Renata Cristina de Campos Pereira; Galvão, Cristina Maria. Integrative literature review: a research method to incorporate evidence in health care and nursing. Texto & Contexto-Enfermagem. 2008;17(4):758-764.
Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan C J, Small EJ, Carroll PR. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017;58(12):1956–1961 Available:https://doi.org/10.2967/jnumed.117.192476
Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougère, C. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. European journal of nuclear medicine and molecular imaging. 2017; 44(1):92–101. Available:https://doi.org/10.1007/s00259-016-3490-6
Wondergem M, Jansen BHE, van der Zant FM, van der Sluis TM, Knol RJJ, van Kalmthout L. WM, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN. Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer. European journal of nuclear medicine and molecular imaging. 2019;46(9):1911–1918. Available:https://doi.org/10.1007/s00259-019-04385-6
Couñago F, Artigas C, Sancho G, Gómez-Iturriaga A, Gómez-Caamaño A, Maldonado A, Caballero B, López-Campos F, Recio M, Del Cerro E, Henríquez I. Importance of 68Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist. PET/TC con 68Ga-PSMA, importancia en la práctica hospitalaria. Visión del oncólogo radioterápico. Revista española de medicina nuclear e imagen molecular. 2018;37(5):302–314 Available:https://doi.org/10.1016/j.remn.2018.07.005
Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M, 3rd, Pinover WH, Beyer DC, Amanie JO, Sandler HM, Kachnic LA. Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. International journal of radiation oncology, biology, physics. 2018;102(2):287–295. Available:https://doi.org/10.1016/j.ijrobp.2018.06.008
Morikawa L, Ferreira CGM. Radioterapia Contemporânea. Atheneu; 2018.
Marzec J, Becker J, Paulsen F, Wegener D, Olthof SC, Pfannenberg C, Schwenck J, Bedke J, Stenzl A, Nikolaou K, la Fougère C, Zips D, Müller AC. 68Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery. Acta oncologica (Stockholm, Sweden). 2020;59(2):149–156 Available:https://doi.org/10.1080/0284186X.2019.1669816
Hironaka FH, Sapienza MT, Ono CR, Lima MS, Buchpiguel CA. Medicina Nuclear: princípio e aplicações. São Paulo: Atheneu; 2012.
Patel PH, Chaw CL, Tree AC, Sharabiani M, van As NJ. Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer. World journal of urology. 2019;37(12):2615–2621. Available:https://doi.org/10.1007/s00345-019-02873-w
Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King C. R, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann, K, Fendler WP, Eiber M, Nickols NG. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018;59(2):230–237 Available:https://doi.org/10.2967/jnumed.117.201749
De Bleser E, Ost P. Reply to Pirus Ghadjar, Thomas Wiegel's Letter to the Editor re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligo Recurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome, Toxicity of Stereotactic Body Radiotherapy, Elective Nodal Radiotherapy. Eur Urol. 2019;76:732-9. European urology. 2020;77(3):e62–e63 Available:https://doi.org/10.1016/j.eururo.2019.11.003
Júnior, Prado et al. Experiência de um ano com PET/CT 68Ga-PSMA: aplicações e resultados na recidiva bioquímica do câncer prostático. Radiologia Brasileira. 2018;51(3):151-155.
Scobioala S, Kittel C, Elsayad K, Kroeger K, Oertel M, Samhouri L, Haverkamp U, Eich HT. A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma. Radiation oncology (London, England). 2019; 14(1):143. Available:https://doi.org/10.1186/s13014-019-1353-6